Last updated January 5, 2022

Pharmacological Therapy for Acute Spinal Cord Injury

RECOMMENDATIONS

Level I

Administration of methylprednisolone (MP) for the treatment of acute spinal cord injury (SCI) is not recommended. Clinicians considering MP therapy should bear in mind that the drug is not Food and Drug Administration (FDA) approved for this application. There is no Class I or Class II medical evidence supporting the clinical benefit of MP in the treatment of acute SCI. Scattered reports of Class III evidence claim inconsistent effects likely related to random chance or selection bias. However, Class I, II, and III evidence exists that high-dose steroids are associated with harmful side effects including death.
6731
Administration of GM-1 ganglioside (Sygen) for the treatment of acute SCI is not recommended.
6731

Recommendation Grading

Overview

Title

Pharmacological Therapy for Acute Spinal Cord Injury

Authoring Organization

Publication Month/Year

March 1, 2013

Document Type

Guideline

External Publication Status

Published

Country of Publication

US

Inclusion Criteria

Female, Male, Adolescent, Adult, Older adult

Health Care Settings

Ambulatory, Hospital, Operating and recovery room

Intended Users

Physician, physical therapist, chiropractor

Scope

Assessment and screening, Diagnosis, Prevention, Management, Treatment

Diseases/Conditions (MeSH)

D013119 - Spinal Cord Injuries

Keywords

spinal cord injury, GM-1 ganglioside, Pharmacologic therapy, Sygen trials, Mehtylprednisolone, NASCIS trials